偏頭痛市場:KOL的洞察

本報告研究了全球偏頭痛市場，並提供了市場概況，以及上市的治療方法、管道趨勢和未來前景。

目錄

摘要整理

現在及未來的治療流程

調查目的

市售治療方法

• 肉毒桿菌毒素（肉毒桿菌毒素A; 艾伯維（AbbVie）
• Aimovig（elenumab/elenumab-aooe，安進/諾華）
• 阿喬比（fremanezumab/fremanezumab-VFRM; Teva）
• Emgality（galcanezumab/galcanezumab-gnlm; 禮來）
• Leyvaux/Leyvaux （Las Miditan， Lilly）
• 烏佈雷爾維（Ubrozepanto; 艾伯維（AbbVie）
• Nurtec ODT/維杜拉 輝瑞）
• Qulipta/Aquipta（atogepant; 艾伯維（AbbVie）
• Vyepti（eptinezumab; 靈北）
• Zabuzupret（Zabegepanto; 輝瑞）

初期階段的開發計劃

口服凝膠和皮下抗CGRP單克隆抗體的當前動力學

偏頭痛治療的未來展望

附錄

Why do many KOLs prefer Teva's Ajovy or Lilly's Emgality over Amgen/Novartis' Aimovig for the preventive management of migraine? Over the next five years, neurologists anticipate subcutaneous anti-CGRP mAbs will challenge Botox as the first-line treatment for migraine prevention, but that use of Lundbeck's Vyepti will remain limited - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

• How do KOLs assess the potential impact of Xeomin, Dysport and prabotulinumtoxinA on the use of AbbVie's well-established Botox?
• Why are experts impressed by AbbVie's Botox+ Qulipta/Aquipta combination trial?
• How do KOLs prescribe Pfizer's Nurtec ODT/Vydura, and what other studies do experts recommend?
• What underpins neurologists' opinion that AbbVie's Qulipta/Aquipta is preferable to Pfizer's Nurtec ODT in the preventive management of migraine?
• Why do neurologists say that despite being an effective treatment, Lilly's lasmiditan is currently reserved for later-line therapy?
• Why are KOLs not particularly impressed by the clinical data for Pfizer's Zavzpret?

Key brands covered in this report:

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (3)

Marketed therapies (137)

• Botox (onabotulinum toxin A; AbbVie) (18)
  • Key insights summary (18)
• Aimovig (erenumab/erenumab-aooe; Amgen/Novartis) (10)
  • Key insights summary (10)
• Ajovy (fremanezumab/fremanezumab-vfrm; Teva) (10)
  • Key insights summary (10)
• Emgality (galcanezumab/galcanezumab-gnlm; Lilly) (10)
  • Key insights summary (10)
• Reyvow/Rayvow (lasmiditan; Lilly) (14)
  • Key insights summary (14)
• Ubrelvy (ubrogepant; AbbVie) (9)
  • Key insights summary (9)
• Nurtec ODT/Vydura (rimegepant; Pfizer) (16)
  • Key insights summary (16)
• Qulipta/Aquipta (atogepant; AbbVie) (16)
  • Key insights summary (16)
• Vyepti (eptinezumab; Lundbeck) (21)
  • Key insights summary (21)
• Zavzpret (zavegepant; Pfizer) (13)
  • Key insights summary (13)

Early-stage development programmes (22)

• Key insights summary (22)
  • KOLs are pleased with the Phase II HOPE trial and are enthusiastic about the potential of PACAP therapy in migraine treatment (20)

Current dynamics of oral gepants and subcutaneous anti-CGRP mAbs (12)

• Key insights summary (12)
  • Better tolerability profile of oral gepants makes them the preferred option over triptans: some KOLs favour subcutaneous mAbs over oral gepants due to adherence issues (10)

Future Outlook for the Migraine Therapies (10)

• Key insights summary (10)
  • Neurologists foresee triptans to remain a standard choice for acute migraine, with gepants being the second line of treatment (8)

Appendix (4)

• KOL details (4)